Search Results 821-830 of 17738 for corticosteroid

1. Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production - Mayo Clinic

   stable without corticosteroids for a minimum of 3 weeks prior to the commencement of the study. Patients with neurologic symptoms must undergo a CT/MRI to ...

2. Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma - Mayo Clinic

   No immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be HIV positive with a CD4 count of < 400/mm³ ...

3. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy - Mayo Clinic

   Intolerance to corticosteroids may include depression, severe insomnia, osteopenia, cushingoid features, etc. Intolerance to AZA/6-MP should include ...

4. A Study to Evaluate PDS0101 and Pembrolizumab Combination to Treat Subjects with HPV16 + Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma - Mayo Clinic

   corticosteroids is acceptable. - Has a known additional malignancy ... corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not

5. A Study of Vedolizumab in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) - Mayo Clinic

   The participant should have completed Study MLN0002-3024 or Study MLN0002-3025 and achieved corticosteroid-free clinical response at Week 54 (and has ...

6. Psoriasis - Symptoms and causes - Mayo Clinic

   Certain medications — including lithium, high blood pressure drugs and antimalarial drugs; Rapid withdrawal of oral or injected corticosteroids. More ...

7. Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion - Mayo Clinic

   Ongoing immunosuppressive therapy other than corticosteroids; Received last dose of study drug on another therapeutic clinical trial within 30 days prior to ...

8. Pulmonary Medicine Clinical Trials - Medical Professionals

   ... corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the ...

9. AIDS and Its Pulmonary Threat - A Mystery Solved - Mayo Clinic News Network

   Patients with moderate to severe PCP likely will be given a corticosteroid in conjunction with the trimethoprim-sulfamethoxazole combination. “PCP once was ...

10. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

    ... corticosteroids, or are on stable dose of corticosteroids for at least 4 weeks prior to study Day 1 are permitted. Subjects currently taking enzyme-inducing ...